此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

IASO206在复发/难治性多发性骨髓瘤患者中的应用

IASO206在复发/难治性多发性骨髓瘤患者中的安全性和有效性的探索性研究

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

研究概览

研究类型

介入性

注册 (估计的)

18

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Tianjin、中国
        • 招聘中
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • 接触:
        • 首席研究员:
          • gang An

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • 18 to 75 years old, male or female;

  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);

  • Presence of measurable lesions during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;

  • ECOG score ≤ 2;

  • Expected survival time ≥12 weeks;

  • Subjects must have adequate organ function:

  • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥50×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤1.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
    • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • Left ventricular ejection fraction (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective contraceptive methods with tools or drugs from the time the subject signs the informed consent form until one year after administration;

  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;

  • Multiple myeloma patients with plasma cell leukemia;

  • Patients with amyloidosis;

  • Patients who have received autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

  • Patients who have received previous BCMA-targeted therapy;

  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;

  • Patients who have received other anti-tumor treatments requires an appropriate washout period:

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of corticosteroids during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;

  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;

  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;

  • Patient who needs chronic use of immunosuppressive agents;

  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;

  • Patients with a history of solid organ transplantation;

  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;

  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;

  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;

  • Patients who have received inactivated vaccines within 4 weeks before enrollment;

  • Women who are pregnant or breastfeeding;

  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;

  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);

  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);

  • Other situations considered unsuitable by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:IASO206

IASO206 will be administered in one infusion.

The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The incidence and severity of adverse events(AEs)
大体时间:up to 2 years after IASO206 infusion

Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus.

All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 2 years after IASO206 infusion

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR)
大体时间:up to 2 years after IASO206 infusion

The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

up to 2 years after IASO206 infusion
Time to response (TTR)
大体时间:up to 2 years after IASO206 infusion

The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

up to 2 years after IASO206 infusion
MRD negativity rate
大体时间:up to 2 years after IASO206 infusion

The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

up to 2 years after IASO206 infusion
Duration of response (DOR)
大体时间:up to 2 years after IASO206 infusion

The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

up to 2 years after IASO206 infusion
Progression-free survival (PFS)
大体时间:up to 2 years after IASO206 infusion

The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

up to 2 years after IASO206 infusion
Overall survival (OS)
大体时间:up to 2 years after IASO206 infusion

The time from the date of IASO206 infusion to the date of death from any reason.

up to 2 years after IASO206 infusion
Pharmacodynamics(PD)
大体时间:up to 2 years after IASO206 infusion

The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

up to 2 years after IASO206 infusion
Pharmacokinetic Analysis(PK)
大体时间:up to 24 month after IASO206 infusion

Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
大体时间:up to 24 month after IASO206 infusion

Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
大体时间:up to 24 month after IASO206 infusion

Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

up to 24 month after IASO206 infusion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月8日

初级完成 (估计的)

2026年12月15日

研究完成 (估计的)

2028年10月15日

研究注册日期

首次提交

2025年12月9日

首先提交符合 QC 标准的

2025年12月22日

首次发布 (实际的)

2026年1月7日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅